Cholesterol screening and statin use in children: a literature review
Atherosclerosis begins in childhood. Fatty streaks, the earliest precursor of atherosclerotic lesions, have been found in the coronary arteries of children of 2 years of age. Hypercholesterolaemia is a risk factor for coronary artery disease. Hypercholesterolaemia can be either primary, when it is characteristic of the main disease, or secondary when it occurs as a result of either a disease process or drug treatment. Given the risk of vascular disease, including myocardial infarction (MI), cerebrovascular accidents (CVA, also known as strokes), peripheral vascular disease (PVD) and ruptured aortic aneurysm, which may follow atherosclerosis, it is important to prevent or slow the early development of atherosclerotic lesions. This prevention necessitates the control of key risk factors such hypercholesterolaemia, dyslipidaemia, hypertension etc. However, at what point this prevention ought to occur, and in what form, is uncertain. Using pharmacological primary prevention for hypercholesterolaemia in the paediatric population is controversial. In an adult patient, hypercholesterolaemia warrants the initiation of a statin. Statins, also known as hydroxymethylglutaryl co-enzyme A inhibitors (or HMG-CoA inhibitors) act by altering cholesterol metabolism. In the paediatric population, the clinical course of vascular disease and the effect of altering this clinical course are less certain. This article reviews the published literature on hypercholesterolaemia in children and the use of statins as a treatment for dyslipidaemia in children. The US National Cholesterol Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents 2012 guidelines (NCEP guidelines) regarding the recognition and treatment of childhood dyslipidaemia are reviewed.
KeywordsCholesterol Dyslipidaemia Hypercholesterolaemia Paediatrics Statins
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This study does not contain any studies with human participants or animals performed by any of the authors.
- 2.HC MG Jr, McMahan CA, Zieske AW et al (2000) Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth: the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb Vasc Biol 20(8):1998–2004CrossRefGoogle Scholar
- 16.Peterson AL, McBride PE (2012) A review of guidelines for dyslipidemia in children and adolescents. WMJ 111(6):271–281Google Scholar
- 17.Holven KB, Narverud I, Lindvig HW et al Subjects with FH are characterized by an inflammatory phenotype despite long-term intensive cholesterol lowering treatment. Atherosclerosis 233(2):561–567Google Scholar
- 19.WHO Human Genetics Programme (1999) Familial hypercholesterolaemia (FH): report of a second WHO consultation, Paris, 3 October 1997. Geneva: World Health Organization.Google Scholar
- 21.Descamps OS, Tenoutasse S, Stephenne X, Gies I, Beauloye V, Lebrethon MC, de Beaufort C, de Waele K, Scheen A, Rietzschel E, Mangano A, Panier JP, Ducobu J, Langlois M, Balligand JL, Legat P, Blaton V, Muls E, van Gaal L, Sokal E, Rooman R, Carpentier Y, de Backer G, Heller FR (2011) Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. Atherosclerosis 218(2):272–280CrossRefGoogle Scholar
- 24.Noto N, Okada T, Abe Y, Miyashita M, Kanamaru H, Karasawa K, Ayusawa M, Sumitomo N, Mugishima H (2011) Changes in the textural characteristics of intima-media complex in young patients with familial hypercholesterolemia: implication for visual inspection on B-mode ultrasound. J Am Soc Echocardiogr 24(4):438–443CrossRefGoogle Scholar
- 28.Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ, Sorlie PD, Sotoodehnia N, Turan TN, Virani SS, Wong ND, Woo D, Turner MB, American Heart Association Statistics Committee and Stroke Statistics Subcommittee (2012) Executive summary: heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 125(1):188–197CrossRefGoogle Scholar
- 31.Ho M, Garnett SP, Baur LA, Burrows T, Stewart L, Neve M, Collins C (2013) Impact of dietary and exercise interventions on weight change and metabolic outcomes in obese children and adolescents: a systematic review and meta-analysis of randomized trials. JAMA Pediatr 167(8):759–768CrossRefGoogle Scholar
- 32.(2011) Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescent. NHLBI. Pediatrics 128(Suppl 5):S213–S256. https://doi.org/10.1542/peds.2009-2107C
- 37.Wilson JMG, Jungner G (1968) Principles and practice of screening for disease. World Health Organization, GenevaGoogle Scholar
- 41.Myśliwiec M, Walczak M, Małecka-Tendera E, Dobrzańska A, Cybulska B, Filipiak K, Mazur A, Jarosz-Chobot P, Szadkowska A, Rynkiewicz A, Chybicka A, Socha P, Brandt A, Bautembach-Minkowska J, Zdrojewski T, Limon J, Gidding SS, Banach M (2014) Management of familial hypercholesterolemia in children and adolescents. Position paper of the Polish Lipid Expert Forum. J Clin Lipidol 8(2):173–180CrossRefGoogle Scholar
- 45.Bradley CB, Harrell JS, McMurray RG (1997) Prevalence of high cholesterol, high blood pressure, and smoking among elementary school children in North Carolina. N C Med J 58(5):362–367Google Scholar
- 55.Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, Gaudet D, Duivenvoorden R, Veltri EP, Marais AD, de Groot E, ENHANCE Investigators (2008) Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 358(14):1431–1443CrossRefGoogle Scholar